• Pazhani Sundaram, Ph.D

    Dr. Sundram has strong experience in protein expression technologies, molecular biology, biochemistry, peptidomimetics and in drug delivery systems. Prior to starting Recombinant Technologies in 1998, he was trained at Yale School of Medicine for a decade. At Yale, Dr. Sundaram contributed in the research and development of a vaccine to treat human papilloma virus in a rabbit model. This work formed the basis for Merck in developing the vaccine for HPV 16, which is currently marketed as 'Gardasil'. Dr. Sundaram's research is acknowledged on the Merck's patent for the above vaccine.

    Dr. Sundaram's research followed by a clinical trial on a herbal medicine for his doctoral thesis research translated to a marketable drug in India to treat coronary heart disease.

  • Robert Friedland, MD

    Robert Friedland, MD is a Professor in Department of Neurology, and is a Mason C. and Mary D. Rudd Endowed Chair In Neurology at University of Louisville School of Medicine, Louisville, KY. He is a devoted clinical and research neurologist focused on dementia, Alzheimer's disease, Parkinson disease and brain aging. He graduated from the Mount Sinai School of Medicine in New York in 1973, and completed his neurology residency at the Mount Sinai Hospital. He was a Fellow in dementia and aging at the Albert Einstein College of Medicine, NY. He served as Chief Neurologist at University California, Berkeley from 1985 to 1990. He was also a Deputy Clinical Director and Chief of the Section on Brain Aging and Dementia of the National Institute on Aging, NIH. He is currently engaged in studies to developing immunological approaches to the treatment of both Alzheimer and Parkinson's diseases.Dr. Friedland has authored or coauthored over 200 scientific publications and has current research funding from the (National Institute on Aging, NIH, as well as several Foundations, Institutes, Corporations and Families.

  • Dinesh Vyas, Ph.D

    Dinesh Vyas has 31 years of industry experience in drug discovery and development. In his tenure at Bristol-Myers Squib, Dr. Vyas participated in the discovery and development of 14 clinical drug candidates with one FDA approved NDA. His contributions earned him the Associate Director, Director, Group Director, and Distinguished Research Fellow positions in BMS. He is an author/coauthor on more than 110 publications and written numerous book chapters and review articles. He is also an inventor/co-inventor on over 40 patents. Currently, he is an active member of the Connecticut Academy of Sciences and Engineering (CASE) and is on the editorial board of Medicinal Research Reviews. He has participated in NIH and CASE study sections.

  • Ranjini Sundaram, Ph.D

    Dr. Ranjini Sundaram, Ph.D. has been actively involved in developing the AmyTrap technology. She is a co-inventor of Amytrap patent. Her contributions have immensely helped RT to move AmyTrap from inception to the current stage of development. She is employed as a Research Faculty at Yale University School of Medicine, and has been consulting RT.

    Her research prior to Yale includes research at two companies including RTneurodegenerative diseases like Alzheimer's disease and Neimann Pick, Type C. Her expertise in protein chemistry, molecular biology and immunology, and her working knowledge in running clinical trials at the Yale Cancer Center and regulatory affairs are valuable assets to RT.